DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages. (15th November 2015)
- Record Type:
- Journal Article
- Title:
- DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages. (15th November 2015)
- Main Title:
- DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages
- Authors:
- Brenner, C.
Franz, W.M.
Kühlenthal, S.
Kuschnerus, K.
Remm, F.
Gross, L.
Theiss, H.D.
Landmesser, U.
Kränkel, N. - Abstract:
- Abstract: Objective: Glipitins are widely used for the treatment of type 2 diabetic patients. In addition to their improvement of glycemic control, animal studies have suggested an independent anti-atherosclerotic effect of gliptins. Nevertheless, recent clinical trials regarding long-term effects of gliptin therapy on vascular events have been disappointing. This discrepancy led us to better dissect the functional role of SDF-1/CXCR4 signaling as a potential mechanism underlying gliptin action. The study should give improved understanding of the potential of gliptin therapy in the prevention and treatment of atherosclerosis. Methods and results: In an ApoE −/− mouse model on high cholesterol diet, long-term treatment with the DPP-4 inhibitor Sitagliptin significantly reduced atherosclerosic plaque load in the aorta. Flow cytometry analyses showed an enrichment of M2 macrophages in the aortic wall under gliptin therapy. Importantly, the number of recruited CD206 + macrophages was inversely correlated with total plaque area while no correlation was found for the overall macrophage population or M1 macrophages. Blockade of CXCR4/SDF-1 signaling by AMD3100 inhibited aortic M2 accumulation and the therapeutic effect of Sitagliptin. Correspondingly, Sitagliptin shifted the polarization profile of macrophages towards a M2-like phenotype. Conclusion: Sitagliptin-mediated inhibition of early atherosclerosis is based on M2-polarization during monocyte differentiation via theAbstract: Objective: Glipitins are widely used for the treatment of type 2 diabetic patients. In addition to their improvement of glycemic control, animal studies have suggested an independent anti-atherosclerotic effect of gliptins. Nevertheless, recent clinical trials regarding long-term effects of gliptin therapy on vascular events have been disappointing. This discrepancy led us to better dissect the functional role of SDF-1/CXCR4 signaling as a potential mechanism underlying gliptin action. The study should give improved understanding of the potential of gliptin therapy in the prevention and treatment of atherosclerosis. Methods and results: In an ApoE −/− mouse model on high cholesterol diet, long-term treatment with the DPP-4 inhibitor Sitagliptin significantly reduced atherosclerosic plaque load in the aorta. Flow cytometry analyses showed an enrichment of M2 macrophages in the aortic wall under gliptin therapy. Importantly, the number of recruited CD206 + macrophages was inversely correlated with total plaque area while no correlation was found for the overall macrophage population or M1 macrophages. Blockade of CXCR4/SDF-1 signaling by AMD3100 inhibited aortic M2 accumulation and the therapeutic effect of Sitagliptin. Correspondingly, Sitagliptin shifted the polarization profile of macrophages towards a M2-like phenotype. Conclusion: Sitagliptin-mediated inhibition of early atherosclerosis is based on M2-polarization during monocyte differentiation via the SDF-1/CXCR4 signaling. In contrast to earlier assumptions gliptin treatment might be especially effective in prevention of atherosclerosis. … (more)
- Is Part Of:
- International journal of cardiology. Volume 199(2015)
- Journal:
- International journal of cardiology
- Issue:
- Volume 199(2015)
- Issue Display:
- Volume 199, Issue 2015 (2015)
- Year:
- 2015
- Volume:
- 199
- Issue:
- 2015
- Issue Sort Value:
- 2015-0199-2015-0000
- Page Start:
- 163
- Page End:
- 169
- Publication Date:
- 2015-11-15
- Subjects:
- Sitagliptin -- Atherosclerosis -- M2 macrophages -- Priming -- SDF-1
Cardiology -- Periodicals
Electronic journals
616.12 - Journal URLs:
- http://www.clinicalkey.com/dura/browse/journalIssue/01675273 ↗
http://www.sciencedirect.com/science/journal/01675273 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.ijcard.2015.07.044 ↗
- Languages:
- English
- ISSNs:
- 0167-5273
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.158000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 8783.xml